Condition: Fanconi Anemia · Severe Aplastic Anemia · Myelodysplastic Syndromes · Sponsor: Masonic Cancer Center, University of Minnesota
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
This description comes directly from the study's public registry record.
Margaret MacMillan, MD, Msc, FRCPC · 612-626-2961 · macmi002@umn.edu
Always discuss trial participation with your own doctor first.
| Masonic Cancer Center at University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03579875